AAPL332.77+0.50 (+0.15%) ▲|ABBV261.89+4.77 (+1.86%) ▲|ABT103.10+1.15 (+1.13%) ▲|ACN190.40+6.50 (+3.53%) ▲|ADBE262.85+10.62 (+4.21%) ▲|AMAT431.29-25.20 (-5.52%) ▼|AMD491.32-24.81 (-4.81%) ▼|AMGN379.28+1.93 (+0.51%) ▲|AMT177.33-0.52 (-0.29%) ▼|AMZN253.97-2.81 (-1.09%) ▼|AVGO347.41-14.58 (-4.03%) ▼|AXP325.23+0.54 (+0.16%) ▲|BA209.45-1.00 (-0.48%) ▼|BAC61.70-1.00 (-1.59%) ▼|BKNG175.91+1.99 (+1.14%) ▲|BLK1,066.20-13.46 (-1.25%) ▼|BMY64.19+0.55 (+0.86%) ▲|BNY159.54-3.12 (-1.92%) ▼|BRK-B513.71+3.34 (+0.65%) ▲|C134.54-4.28 (-3.08%) ▼|CAT786.89-31.68 (-3.87%) ▼|CL88.32+1.52 (+1.75%) ▲|CMCSA25.08-0.13 (-0.50%) ▼|COF205.93-2.37 (-1.14%) ▼|COP138.16+0.81 (+0.59%) ▲|COST916.02+11.25 (+1.24%) ▲|CRM256.53+8.81 (+3.56%) ▲|CSCO110.96-1.17 (-1.04%) ▼|CVS95.35+0.69 (+0.72%) ▲|CVX214.42+0.36 (+0.17%) ▲|DE687.34+11.60 (+1.72%) ▲|DHR199.93-0.21 (-0.10%) ▼|DIS108.66+2.11 (+1.98%) ▲|DUK118.78-0.64 (-0.54%) ▼|EMR147.94-4.26 (-2.80%) ▼|FDX312.60+1.83 (+0.59%) ▲|GD357.05+1.15 (+0.32%) ▲|GE317.11-6.55 (-2.02%) ▼|GEV876.00-81.27 (-8.49%) ▼|GILD145.53+1.81 (+1.26%) ▲|GM86.22+0.60 (+0.70%) ▲|GOOG342.05+6.60 (+1.97%) ▲|GOOGL345.39+6.89 (+2.03%) ▲|GS1,000.43-28.75 (-2.79%) ▼|HD309.87+1.13 (+0.36%) ▲|HON199.26-3.11 (-1.53%) ▼|IBM247.76+4.47 (+1.84%) ▲|INTC97.90-5.04 (-4.90%) ▼|INTU338.12+16.55 (+5.15%) ▲|ISRG374.04+4.89 (+1.32%) ▲|JNJ268.52+2.94 (+1.11%) ▲|JPM350.88-5.35 (-1.50%) ▼|KO88.91+0.62 (+0.70%) ▲|LIN462.96-3.27 (-0.70%) ▼|LLY1,146.89+31.19 (+2.80%) ▲|LMT529.15+4.96 (+0.95%) ▲|LOW197.92+1.10 (+0.56%) ▲|LRCX277.89-20.33 (-6.82%) ▼|MA575.11+5.92 (+1.04%) ▲|MCD257.99+5.46 (+2.16%) ▲|MDLZ62.29-0.15 (-0.24%) ▼|MDT93.12+2.16 (+2.37%) ▲|META659.63+11.60 (+1.79%) ▲|MMM160.99-3.98 (-2.41%) ▼|MO70.54+1.56 (+2.25%) ▲|MRK144.78+0.85 (+0.59%) ▲|MS209.52-4.87 (-2.27%) ▼|MSFT505.28+9.65 (+1.95%) ▲|MU924.41-50.85 (-5.21%) ▼|NEE81.85-0.47 (-0.56%) ▼|NFLX80.37+2.97 (+3.84%) ▲|NKE37.22+0.42 (+1.13%) ▲|NOW141.65+9.12 (+6.88%) ▲|NVDA211.93-6.36 (-2.91%) ▼|ORCL144.70-5.59 (-3.72%) ▼|PEP136.24-0.08 (-0.06%) ▼|PFE27.77+0.05 (+0.19%) ▲|PG146.06+0.79 (+0.54%) ▲|PLTR171.55+4.32 (+2.58%) ▲|PM193.36+2.30 (+1.20%) ▲|QCOM178.71-3.26 (-1.79%) ▼|RTX195.24-2.44 (-1.23%) ▼|SBUX98.44-0.30 (-0.30%) ▼|SCHW107.43+0.18 (+0.17%) ▲|SO86.82-0.35 (-0.40%) ▼|SPG206.10+1.27 (+0.62%) ▲|T26.28+0.22 (+0.84%) ▲|TMO607.77-2.05 (-0.34%) ▼|TMUS183.13+0.80 (+0.44%) ▲|TSLA363.34-2.10 (-0.57%) ▼|TXN263.67-5.03 (-1.87%) ▼|UBER72.27+0.60 (+0.84%) ▲|UNH384.35+7.58 (+2.01%) ▲|UNP283.89-0.52 (-0.18%) ▼|UPS101.70+1.42 (+1.42%) ▲|USB62.82-0.02 (-0.03%) ▼|V376.00+5.55 (+1.50%) ▲|VZ51.13+0.52 (+1.02%) ▲|WFC88.54-1.75 (-1.94%) ▼|WMT109.06+1.91 (+1.78%) ▲|XOM165.91-0.09 (-0.05%) ▼|AAPL332.77+0.50 (+0.15%) ▲|ABBV261.89+4.77 (+1.86%) ▲|ABT103.10+1.15 (+1.13%) ▲|ACN190.40+6.50 (+3.53%) ▲|ADBE262.85+10.62 (+4.21%) ▲|AMAT431.29-25.20 (-5.52%) ▼|AMD491.32-24.81 (-4.81%) ▼|AMGN379.28+1.93 (+0.51%) ▲|AMT177.33-0.52 (-0.29%) ▼|AMZN253.97-2.81 (-1.09%) ▼|AVGO347.41-14.58 (-4.03%) ▼|AXP325.23+0.54 (+0.16%) ▲|BA209.45-1.00 (-0.48%) ▼|BAC61.70-1.00 (-1.59%) ▼|BKNG175.91+1.99 (+1.14%) ▲|BLK1,066.20-13.46 (-1.25%) ▼|BMY64.19+0.55 (+0.86%) ▲|BNY159.54-3.12 (-1.92%) ▼|BRK-B513.71+3.34 (+0.65%) ▲|C134.54-4.28 (-3.08%) ▼|CAT786.89-31.68 (-3.87%) ▼|CL88.32+1.52 (+1.75%) ▲|CMCSA25.08-0.13 (-0.50%) ▼|COF205.93-2.37 (-1.14%) ▼|COP138.16+0.81 (+0.59%) ▲|COST916.02+11.25 (+1.24%) ▲|CRM256.53+8.81 (+3.56%) ▲|CSCO110.96-1.17 (-1.04%) ▼|CVS95.35+0.69 (+0.72%) ▲|CVX214.42+0.36 (+0.17%) ▲|DE687.34+11.60 (+1.72%) ▲|DHR199.93-0.21 (-0.10%) ▼|DIS108.66+2.11 (+1.98%) ▲|DUK118.78-0.64 (-0.54%) ▼|EMR147.94-4.26 (-2.80%) ▼|FDX312.60+1.83 (+0.59%) ▲|GD357.05+1.15 (+0.32%) ▲|GE317.11-6.55 (-2.02%) ▼|GEV876.00-81.27 (-8.49%) ▼|GILD145.53+1.81 (+1.26%) ▲|GM86.22+0.60 (+0.70%) ▲|GOOG342.05+6.60 (+1.97%) ▲|GOOGL345.39+6.89 (+2.03%) ▲|GS1,000.43-28.75 (-2.79%) ▼|HD309.87+1.13 (+0.36%) ▲|HON199.26-3.11 (-1.53%) ▼|IBM247.76+4.47 (+1.84%) ▲|INTC97.90-5.04 (-4.90%) ▼|INTU338.12+16.55 (+5.15%) ▲|ISRG374.04+4.89 (+1.32%) ▲|JNJ268.52+2.94 (+1.11%) ▲|JPM350.88-5.35 (-1.50%) ▼|KO88.91+0.62 (+0.70%) ▲|LIN462.96-3.27 (-0.70%) ▼|LLY1,146.89+31.19 (+2.80%) ▲|LMT529.15+4.96 (+0.95%) ▲|LOW197.92+1.10 (+0.56%) ▲|LRCX277.89-20.33 (-6.82%) ▼|MA575.11+5.92 (+1.04%) ▲|MCD257.99+5.46 (+2.16%) ▲|MDLZ62.29-0.15 (-0.24%) ▼|MDT93.12+2.16 (+2.37%) ▲|META659.63+11.60 (+1.79%) ▲|MMM160.99-3.98 (-2.41%) ▼|MO70.54+1.56 (+2.25%) ▲|MRK144.78+0.85 (+0.59%) ▲|MS209.52-4.87 (-2.27%) ▼|MSFT505.28+9.65 (+1.95%) ▲|MU924.41-50.85 (-5.21%) ▼|NEE81.85-0.47 (-0.56%) ▼|NFLX80.37+2.97 (+3.84%) ▲|NKE37.22+0.42 (+1.13%) ▲|NOW141.65+9.12 (+6.88%) ▲|NVDA211.93-6.36 (-2.91%) ▼|ORCL144.70-5.59 (-3.72%) ▼|PEP136.24-0.08 (-0.06%) ▼|PFE27.77+0.05 (+0.19%) ▲|PG146.06+0.79 (+0.54%) ▲|PLTR171.55+4.32 (+2.58%) ▲|PM193.36+2.30 (+1.20%) ▲|QCOM178.71-3.26 (-1.79%) ▼|RTX195.24-2.44 (-1.23%) ▼|SBUX98.44-0.30 (-0.30%) ▼|SCHW107.43+0.18 (+0.17%) ▲|SO86.82-0.35 (-0.40%) ▼|SPG206.10+1.27 (+0.62%) ▲|T26.28+0.22 (+0.84%) ▲|TMO607.77-2.05 (-0.34%) ▼|TMUS183.13+0.80 (+0.44%) ▲|TSLA363.34-2.10 (-0.57%) ▼|TXN263.67-5.03 (-1.87%) ▼|UBER72.27+0.60 (+0.84%) ▲|UNH384.35+7.58 (+2.01%) ▲|UNP283.89-0.52 (-0.18%) ▼|UPS101.70+1.42 (+1.42%) ▲|USB62.82-0.02 (-0.03%) ▼|V376.00+5.55 (+1.50%) ▲|VZ51.13+0.52 (+1.02%) ▲|WFC88.54-1.75 (-1.94%) ▼|WMT109.06+1.91 (+1.78%) ▲|XOM165.91-0.09 (-0.05%) ▼|
22.2 C
New York
Monday, September 14, 2026

Tag: collaboration

Marelli’s decarbonization targets approved by the Science Based Targets initiative

The company has committed to an overall net-zero target across the value chain by 2045 SOUTHFIELD, Mich., June 18, 2025 /PRNewswire/ -- Marelli, a global...

Dassault Aviation: Collaboration between AMIAD and Dassault Aviation

Collaboration between AMIAD and Dassault Aviation

Human Appeal announces summertime UK Comedy Tour

One of the UK’s leading humanitarian aid charities, Human Appeal, launched its first summer comedy tour after its successful UK winter comedy tours.

Cymbio Partners with SAP, Delivering Multi-Channel Expansion Solution with Integration to SAP Commerce Cloud

By integrating with SAP Commerce Cloud, Cymbio delivers Multi-Channel Expansion, an end-to-end marketplace automation solution, to help brands effortlessly scale their sales across hundreds...

Solventum Named a Best Company to Work for by U.S. News & World Report

Recognized among the top 25 percent of companies in healthcare and research, and top 25 percent of companies in the Midwest in just 14...

Oklahoma Cancer Specialists and Research Institute Selects BioCareSD and AllyGPO as Primary Drug Distributor and GPO Partner

TULSA, Okla., June 18, 2025 /PRNewswire/ -- Oklahoma Cancer Specialists and Research Institute (OCSRI), a leading independent community oncology practice, has officially selected BioCareSD and AllyGPO as its primary...

HKUST Ranks Among World’s Top 20 and Hong Kong #1 in THE Impact Rankings

HKUST Experts Share Insights at Global Sustainability Development Congress in Istanbul HONG KONG, June 18, 2025 /PRNewswire/ -- The Hong Kong University of Science and...

VectorCare and CSI Aviation Partner to Advance Medical Transport Logistics

SAN FRANCISCO and ALBUQUERQUE, N.M., June 18, 2025 /PRNewswire/ -- VectorCare, a leading provider of patient logistic technology, and CSI Aviation, a globally recognized...

SATO finalises land acquisition in Kauklahti

SATO Corporation, Press release 16 June 2025 at 15:30 PM

Anova Launches Fastest CME to London Service for Financial Markets

New Route Reshaping Global Financial Connectivity CHICAGO, June 18, 2025 /PRNewswire/ -- Anova Financial Networks (AFN), an international carrier and market data provider, has partnered with an...

Solar Power at the Edge of the Arctic: Sungrow Powers one of the worlds Northernmost large-scale PV Project

SIMO, Finland, June 18, 2025 /PRNewswire/ -- Sungrow, global leader in PV inverter and energy storage system (ESS) solutions, has supplied 180 units of...

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWSWIRE) --  Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the efficacy and safety of omaveloxolone in children with Friedreich ataxia (FA) between the ages of 2 to <16. Both non-ambulatory and ambulatory participants may qualify for the study. Participants will be randomized 2:1 to receive omaveloxolone or placebo once a day for 52 weeks before having the opportunity to move into the open-label extension (OLE). Currently, omaveloxolone is commercialized under the brand name SKYCLARYS® in over 40 countries, including in the U.S. and the European Union, and is the only approved product for FA in adults and adolescents aged 16 years and older.

Remepy’s Mobile App Shown to Rewire Brain, Modulate Immune System and Improve Mood in Adults with Subjective Cognitive Decline

RMPY-008 is the first app-based intervention to demonstrate rapid modulation of inflammatory blood biomarkers, acting like a digital antibody in just three weeks Finding from...

HTHK and Huawei Sign Strategic MoU on Deployment of Cloud-native Intelligent Infrastructure

Leveraging AI to accelerate network transformation and elevate user experience SHANGHAI, June 18, 2025 /PRNewswire/ -- Hutchison Telecommunications (Hong Kong) Limited (HTHK) and Huawei International Company Limited...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCollaboration